A trial looking at Xilonix for bowel cancer

Overview

Cancer types:

Bowel (colorectal) cancer, Colon cancer, Rectal cancer, Secondary cancers

Status:

Results

Phase:

Phase 3

Details

This trial looked at Xilonix for bowel cancer that had grown despite having . It was for people whose cancer couldn’t be removed with surgery, or had spread to other parts of the body.

Xilonix is also called bermekimab and MABp1.

The trial was open for people to join in 2014 and 2015. The team published the results in 2017. There is a link to more information in the ‘Summary of results’ section below.

Recruitment start: 20 May 2014

Recruitment end: 2 September 2015